The options paper acknowledged that the need for multiple submissions could delay funded patient access for several years. Yet it effectively accepted them as an intractable feature of our HTA systems.
The process does not cause delays, it promotes them for the best medicines
August 5, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?
August 17, 2026 - - Latest News -
Pharmac aims to pivot toward faster process and broader value framework
August 17, 2026 - -
The 'Dispatched' Podcast - Series 5. Ep.28
August 16, 2026 - - Podcast -
Melbourne biotech pursues an oral path to changing Type 1 diabetes
August 14, 2026 - - Australian Biotech -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech

